Investigation of the effect of interalipid on aluminum phosphide poisoning

Evaluation of the effect of intralipid in the treatment of patients with phosphide poisoning

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220618055207N1

Enrollment

Registered

2022-09-06

Start date

2020-03-20

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aluminium phosphide poisoning. Toxic effect of phosphorus and its compounds, intentional self-harm

Interventions

Intervention 1: Intervention group: In addition to the usual treatment of aluminum phosphide poisoning, Serum Intralipid was administered as a bolus dose of 1.5ml/kg and maintenance dose of 0.25-0.5ml

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: aluminum phosphide poisoning Metabolic acidosis (bicarbonate less than 14) during the first 6 hours

Exclusion criteria

Exclusion criteria: Dissatisfaction of patients simultaneous poisoning (multidrug toxicity)

Design outcomes

Primary

Measure	Time frame
Heart rate, systolic blood pressure, acidosis and arterial blood pH, death. Timepoint: At the beginning of the study and 24 hours after the start of the intervention. Method of measurement: Vital Sign Monitor in icu.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr . Mohammad Arefi

Tehran University of Medical Sciences

armaniair@yahoo.com+98 21 5565 8500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026